Asprosin Level in Individuals with Periodontal Disease

NCT ID: NCT06627972

Last Updated: 2024-10-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2022-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to investigate the levels of asprosin hormone and tumour necrosis factor alpha (TNF-α) in gingival crevicular fluids and to compare its level with those in saliva and serum in patients with gingivitis and periodontitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is investigating the level of asprosin hormone in gingival crevicular fluid of patients with periodontal diseases such as gingivitis and periodontitis, and observing the healthy patient in terms of the hormone levels, as well. 75 volunteer patients aged 18-45 years old were included in this study. These patients were divided equally to three groups: Group I; periodontal health, Group II; gingivitis, Group III; periodontitis.The body fluids including serum, saliva and gingival crevicular fluid were collected from this participants according to the proper protocol and their storage was provided under certain conditions. ELISA tests for asprosin and Tumour necrosis factor alpha were made in laboratory. Also, clinical measurements such as plaque index, bleeding on probing, probing pocket depth were recorded at first visit day of the participants. The data were analysed according to the different periodontal conditions, and correlated with asprosin hormone and tumour necrosis factor alpha level in gingival crevicular fluid, serum and saliva.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontitis Periodontal Health Gingivitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

periodontal health group

Periodontal parameters were recorded at first visit and the fluid samples were collected from participants.

No interventions assigned to this group

Gingivitis group

Periodontal parameters were recorded at first visit and the fluid samples were collected from participants.

No interventions assigned to this group

periodontitis group

Periodontal parameters were recorded at first visit and the fluid samples were collected from participants.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Those with any systemic disease
* Individuals who take medication regularly
* Pregnant or lactating women
* Individuals with menopause and anthropause
* Those who have undergone any periodontal treatment in the last six months
* Smokers
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mustafa Kemal University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Osman Fatih Arpag

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Abdulsamet Tanık, PhD

Role: STUDY_CHAIR

Adiyaman University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Adiyaman University, Faculty of Dentistry

Adıyaman, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Shojaee M, Fereydooni Golpasha M, Maliji G, Bijani A, Aghajanpour Mir SM, Mousavi Kani SN. C - reactive protein levels in patients with periodontal disease and normal subjects. Int J Mol Cell Med. 2013 Summer;2(3):151-5.

Reference Type BACKGROUND
PMID: 24551806 (View on PubMed)

Gul SNS, Eminoglu DO, Laloglu E, Aydin T, Dilsiz A. Salivary and serum asprosin hormone levels in the 2018 EFP/AAP classification of periodontitis stages and body mass index status: a case-control study. Clin Oral Investig. 2024 Jan 13;28(1):91. doi: 10.1007/s00784-024-05494-9.

Reference Type BACKGROUND
PMID: 38217801 (View on PubMed)

de Molon RS, Rossa C Jr, Thurlings RM, Cirelli JA, Koenders MI. Linkage of Periodontitis and Rheumatoid Arthritis: Current Evidence and Potential Biological Interactions. Int J Mol Sci. 2019 Sep 13;20(18):4541. doi: 10.3390/ijms20184541.

Reference Type BACKGROUND
PMID: 31540277 (View on PubMed)

Afacan B, Ozturk VO, Pasali C, Bozkurt E, Kose T, Emingil G. Gingival crevicular fluid and salivary HIF-1alpha, VEGF, and TNF-alpha levels in periodontal health and disease. J Periodontol. 2019 Jul;90(7):788-797. doi: 10.1002/JPER.18-0412. Epub 2018 Dec 11.

Reference Type BACKGROUND
PMID: 30536725 (View on PubMed)

Tutus S, Tanik A, Arpag OF, Onderci M. Is there a relationship between periodontal conditions and asprosin levels in gingival crevicular fluid, saliva and serum? BMC Oral Health. 2025 Apr 29;25(1):651. doi: 10.1186/s12903-025-06014-1.

Reference Type DERIVED
PMID: 40301876 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DHFDUP/2022-0002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.